Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook
That will not change under my direction, and much of my experience is in oncology and leading business transactions.
- That will not change under my direction, and much of my experience is in oncology and leading business transactions.
- However, many issues and limitations are associated with the use of chemotherapy.
- Many patients simply cannot tolerate a chemotherapy dose high enough to benefit from its use due to chemotherapy’s toxic side effects.
- Working in our favor are deep management and R&D teams that have significant and direct experience in clinical drug development.